Lyme disease vaccine shows over 70% efficacy, but phase three misses main goal

An experimental vaccine for Lyme disease is broadly effective, pharmaceutical companies Pfizer and Valneva announced Monday; however, the latter firm’s shares fell because the clinical trial did not reach its main goal.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup